Anonymousabout 2 hours ago
A landmark 23andMe study of nearly 28,000 GLP-1 drug users, published in Nature in April 2026, identified specific variants in the GLP1R and GIPR genes that predict both weight-loss efficacy and the likelihood of nausea and vomiting — raising immediate questions about whether genetic screening should precede prescribing. But experts caution the effect sizes are modest, the data is self-reported, and the cohort skews heavily toward European-ancestry women, meaning the findings are far from ready to reshape clinical practice for the millions of Americans now taking semaglutide or tirzepatide.